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I t has been shown t h a t Herpes Simplex Virus (HSV) and
Varicella-zoster Virus (VZV) share antigenic determinants and t h a t t h e VZV genome contains homologous regions t o HSV-1 and HSV-2 genomes. More recently Edson, e t a l , found t h a t t h e envelope glycoproteins HSV gB and VZV gp63 share comnon antigens and t h a t cross r e a c t i v e anti-HSV polyclonal and monoclonal antibody can n e u t r a l i z e VZV infection. Because of t h e s e common antigens, we sought t o determine i f administration of LVV i n c h i l d r e n can cause cross-reactive immune responses which could confer p a r t i a l immunity t o t h e heterologous viruses. Blood was obtained fran 43 children a t t h e time of LVV vaccine and t h r e e months l a t e r . A control group of 36 age matched children were t e s t e d t o determine seroconversion r a t e s in t h e absence of vaccine. Antibody response was determined by enzyme-linked immunosorbent assay. A sero-negative range f o r HSV and f o r CMV was established by studying sera obtained from 200 i n d i v i d u a l s of varying ages including newborns, i n f a n t s , and adults. Seroconversion r a t e f o r t h e immunized population was 0 of 43 i n f a n t s f o r HSV and 1 of 40 f o r CMV; respective r a t e s f o r t h e control population were 2 of 35 and 1 of 36. (NS) W e conclude t h a t immunization with LVV vaccine o f f e r s no heterologous antibody protection t o HSV and CMV i n children. (NEJM 1986; 315) . We now report the IgG subclass composition of Hib PS AB i n VP who recovered from i n f e c t i o n , and t h e i r IgG responses t o Pn vaccine. 14/41 ( : A X ) VP were considered to be AB responders t o Hib disease ( > 1 ug/ml of Hib PS Ab i n convalescent s e r a a s measured by a Farr assay) compared with 14/25 (56%) unvaccinated p a t i e n t s with Hib disease of s i m i l a r ages (Px.08). In 10 responder VP (mean age=34 mo), the geo. mean convalescent IgG, G 1 and G2 Hib PS AB a s aeasured by ELISA, were 0.97, 0.69 and 0.09 pg/ml, respectively. The IgG and G1 values were 10-fold lower than those i n convalescent s e r a from 14 unvaccinated responder p a t i e n t s (mean age = 37 mo) (9.24, 7.37 and 0.2 pg/ml, respectively; P<0.01). 18 of 41 tiib VP (mean age of 40 mo) were vaccinated with 23-valent Pn PS. They showed s i g n if i c a n t increases i n geo. mean recip. serum IgG t i t e r s t o P-3 (107 to 1936, P<0.001) and t o P-23 (52 t o 120, P<0.02). However, the geo. mean Pn t i t e r s i n post-immune serum of t h e Hib VP group were lower than those of 15 immunized healthy children (mean age=41 mo) (P-3: 3350, P<0.05; P-23: 279, P=0.10). Thus, VP have d e f i c i e n t IgG responses to Hib PS following recovery from Hib disease, and the subclass most affected is GI. Hib VP can respond t o Pn PS vaccine but t h e i r IgG responses a r e lover than those of healthy children.
IGG RESPONSES TO H. INFLUENZAE TYPE B (HIB) AND PNEUMOCOCCAL (PN)-TYPES
Hib PS-vaccinated ~a t i e n t s (VP) who d e v e l o~ Hib d i s e a s e have d e f i c i e n t serum antibody (~~) ' r e $~o n s e s t o ~i b PS d e s p i t e normal concentrations of I g and tetanus AB
DERMAL REACTIVITf TO HUMAN CYTOMEGALOVIRUS (CMV).
Renu Gupta. Eva Gonczol. John Ianacone. Karen Connor. Stanle A. Plotkin. Division of I n f e c t i o u s Diseases. The C L l d r e n t s Hospital of Philadelphia. and t h e Wistar I n s t i t u t e . Philadelphia, PA.
A s k i n t e s t f o r immunity t o human CMV i s described i n which s k i n induration i s measured a f t e r intradermal i n j e c t i o n of heat-inactivated Tome s t r a i n CMV antigen. Randomly s e l e c t e d healthy young adult males and non-pregnant females were prescreened f o r evidence of p a s t i n f e c t i o n with CMV using a l a t e x agglutination t e s t . Each individual was inoculated with 100 ul of tc::t srqtieen (50 ug) prepared from serum-free supernatants of CMV-infected MRC-5 c e l l s (inactivated a t 560C f o r 6 h r s ) . Candida e x t r a c t (1:1000) and non-infected MRC-5 c e l l l y s a t e s . CMV s e r o p o s i t i v e individuals e l i c i t e d p o s i t i v e s k i n reactions t o both t h e Candida e x t r a c t and t h e t e s t antigen. No response was observed a t t h e MRC-5 c e l l l y s a t e inoculation s i t e . Seronegative individuals who were negative t o t h e t e s t antigen a t t h e s t a r t of t h e study, developed a p o s i t i v e response 8 days a f t e r intramuscular immunization with l i v e attenuated Tome s t r a i n CMV. This response a l s o c o r r e l a t e d with i n v i t r o CMV-induced lymphocyte p r b l i f e r a t i o n of p e r i p h e r a l blood lymphocytes from t h e immunized individuals and p e r s i s t e d f o r a t l e a s t 93 days.
In guinea pig experiments with human W. those a n i n~a l s immunized with p u r i f i e d CMV. a v i r u s envelope preparation, o r a 130-55K glycoprotein complex ( i s o l a t e d by immunoadsorbent column chromatography), developed strong skin reactions t o intradermal i n j e c t i o n of 5 ug of each of these antigens. A weak reaction was a l s o observed t o v i r a l capsid antigen. No reactions were observed i n non-immune animals.
